Bio-Nucleonics FDA approved drug, Biostron™ (Strontium Chloride Sr-89 Injection), offers non-narcotic relief to ease the pain of cancer that has spread to bone in advanced stage breast or prostate cancer. Biostron™ Injection is the only generic alternative to the branded version and is the first therapeutic injectable radiopharmaceutical generic to be approved by the U.S. Food and Drug Administration (FDA).

According to the American Cancer Society, approximately 1.4 million new cases of invasive cancer were diagnosed in the U.S. in 2008. The disease is expected to eventually spread to bone that requires some form of intervention in about 75% of breast cancer patients, 70% of prostate cancer patients, and 40% of lung cancer patients. Although not a cure, Strontium Sr-89 Chloride can Injection USP can improve the quality-of-life for many patients.

The Gynocyte® is a major advancement in low dose rate brachytherapy treatment, revolutionizing management and success rates. Brachytherapy, also known as sealed source radiotherapy, is a form of radiation therapy where a radioactive source is placed inside or next to the area requiring treatment, such as in the uterine cervix, enabling localized, precise and minimally-invasive cancer treatment while reducing the radiation exposure in the surrounding healthy tissues. Bio-Nucleonics received FDA marketing clearance for the Gynocyte® as a single-use brachytherapy device for treatment of gynecological and cervical cancers.

Cervical cancer is the number two cause of cancer deaths among women, after breast cancer According to the American Cancer Society, an estimated 40,000 cases of cancer of the uterine corpus (body of the uterus), most often in the endometrium (lining of the uterus), were diagnosed in 2008. A Center for Disease Control (CDC) study has shown that over 25% of women between the ages of 14 and 59 are infected with the human papilloma virus (HPV). Around 2% of these women will get cervical cancer and with treatment, many will survive and live normal, healthy lives. More than $2 billion a year is spent in the U.S. on the treatment of cervical cancer. The International Agency for Research on Cancer estimates that there were approximately 250,000 deaths from cervical cancer in 2005.